We and others have previously shown that metabolic dysfunction, weight gain, and adipocyte hypertrophy are associated with increased production of FGF-1 in subcutaneous adipose tissue [45, 51], and activation of FGFR signaling is associated with tumor growth and resistance to endocrine therapy [45, 52]. This evidence concerns the gene FGF1 and neoplasm.